文献速递神经肌肉病

临床实践中放射免疫沉淀法检测乙酰胆碱受体抗体假阳性的风险

Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice.
PubMed 文献 · Neurology · 2025-04-17

该研究回顾性分析了2003-2022年意大利萨萨里大学医院连续检测AChR-IgG的4795例疑似MG患者,其中445例阳性,362例纳入分析,50例(13.8%)为非肌无力患者。RIPA检测AChR-IgG的阳性预测值为86.2%(95%CI 82.2-89.6),特异性为98.9%(95%CI 98.5-99.2);抗体滴度≥1 nmol/L时阳性预测值升至96.6%(95%CI 94-98.3)。假阳性与低抗体滴度相关,滴度0.5-0.9 nmol/L且临床低概率时应谨慎。

要点

  • RIPA检测AChR-IgG的阳性预测值为86.2%,特异性98.9%。
  • 非肌无力患者抗体滴度中位数0.7 nmol/L,低于MG患者的6 nmol/L。
  • 滴度≥1 nmol/L时阳性预测值提高至96.6%。

核心结论

  • 临床实践中RIPA法检测AChR-IgG可出现假阳性,且与低抗体滴度相关。
  • 滴度在0.5-0.9 nmol/L且临床低概率时需谨慎,避免误诊和不适当治疗。

研究设计与样本

  • 回顾性研究,连续纳入2003-2022年萨萨里大学医院检测AChR-IgG的疑似MG患者4795例。
  • 445例阳性,排除83例信息不足,最终分析362例AChR-IgG阳性患者。
  • 由2名研究者复查病历,定义假阳性为非肌无力表现或症状可由其他诊断更好解释。

主要发现

  • 362例AChR-IgG阳性患者中50例(13.8%)为非肌无力。
  • 阳性预测值86.2%(95%CI 82.2-89.6),特异性98.9%(95%CI 98.5-99.2)。
  • 非肌无力患者较MG患者年轻(中位65岁 vs 38岁)、女性比例更高(74% vs 49.8%)、抗体滴度更低(中位0.7 vs 6 nmol/L)。
  • 非肌无力患者后续转阴比例更高(55% vs 8%)。
  • 滴度≥1 nmol/L时阳性预测值96.6%(95%CI 94-98.3)。

关键数值与推荐

  • 假阳性定义:临床表型不符合MG和/或症状可由其他诊断更好解释。
  • 非肌无力患者的替代诊断包括眼科疾病8例、风湿病7例、假性上睑下垂5例、肌病4例、功能性疾病3例、颅神经麻痹2例、帕金森综合征2例、脱髓鞘疾病2例、其他17例。
  • 7例非肌无力患者血清经固定细胞法复核,6例阴性,1例仅对胎儿型AChR亚型阳性。

临床怎么用

  • RIPA检测AChR-IgG阳性时需结合临床概率评估,低滴度(0.5-0.9 nmol/L)且低概率时警惕假阳性。
  • 对疑似假阳性者可考虑固定细胞法复核。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Radioimmunoprecipitation assay (RIPA) is the gold standard for acetylcholine receptor (AChR)-immunoglobulin G (IgG) detection in patients with myasthenia gravis (MG), with a reported specificity of ≈99%. The risk of "false" AChR-IgG positivity in clinical practice is often considered negligible, although data on large, real-life populations are scarce. The objective of this study was to determine the positive predictive value (PPV) and risk of false AChR-IgG positivity with RIPA in a large cohort of patients with suspected MG. METHODS: We retrospectively identified patients consecutively tested for AChR-IgG by RIPA at the University-Hospital of Sassari over 20 years (2003-2022) (n = 4,795). Medical records of AChR-IgG-positive patients (titer ≥0.5 nmol/L) were reviewed by 2 investigators to identify nonmyasthenic cases with false antibody positivity, defined as follows: (1) clinical phenotypes not consistent with MG and/or (2) symptoms better explained by alternative diagnoses. The characteristics of myasthenic and nonmyasthenic patients with AChR-IgG positivity were compared. A sample of nonmyasthenic patients was retested by fixed cell-based assay (CBA). RESULTS: Among 445 of 4,795 patients testing positive for AChR-IgG during the study period, 83 were excluded (insufficient information). Of 362 AChR-IgG-positive patients included, 50 (13.8%) were designated as nonmyasthenic. The PPV and specificity were 86.2% (95% CI 82.2-89.6) and 98.9% (95% CI 98.5-99.2), respectively. Alternative diagnoses in nonmyasthenic patients included ophthalmologic diseases (n = 8), rheumatic diseases (n = 7), pseudoptosis (n = 5), myopathy (n = 4), functional disorders (n = 3), cranial nerve palsy (n = 2), parkinsonism (n = 2), demyelinating diseases (n = 2), and others (n = 17). Compared with patients with MG, nonmyasthenic patients were younger (median age 65 [range 7-91] vs 38 [range 5-80] years), more frequently female (155/312 [49.8%] vs 37/50 [74%]), had lower AChR-IgG titers (median 6 [range 0.5-28] vs 0.7 [range 0.5-5.5] nmol/L), and were more likely to become seronegative on subsequent tests (9/120 [8%] vs 6/11 [55%]). After stratification by titer ≥1 nmol/L, the PPV increased to 96.6% (95% CI 94-98.3). Serum of 7 nonmyasthenic patients was retested by CBA, giving negative results (n = 6) or selective positivity against the fetal AChR isoform (n = 1). DISCUSSION: False AChR-IgG positivity may occur in clinical practice with RIPA and associates with low antibody titer. Caution is needed when titers between 0.5 and 0.9 nmol/L are detected in low-probability situations because failure to recognize false antibody positivity may lead to misdiagnosis and inappropriate treatments.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Zara P, Chessa P, Deiana GA, et al. Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice. Neurology. 2025. PMID: 40245350. doi:10.1212/WNL.0000000000213498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。